Quantum Cyber N.V. has made a significant leadership change by appointing David Caplon as its new Chief Financial Officer (CFO) following the resignation of William Caragol. This transition, effective November 20, 2026, is expected to enhance the company's financial strategy and operations.
William Caragol's resignation marks a pivotal moment for Quantum Cyber, a company focused on pharmaceutical preparations. To support the transition, Caragol has entered into a consulting agreement with the company, ensuring continuity in financial oversight during this period of change.
Background
Quantum Cyber N.V. operates in the pharmaceutical preparations sector, as classified under the Standard Industrial Classification (SIC) code 2834. The company trades on the Nasdaq under the ticker symbol QUCY. Quantum Cyber has been active in recent filings, including an 8-K on November 13, 2026, and a 10-Q on November 12, 2026. The organization is classified as an emerging growth company.
What the Filing Says
The recent SEC filing indicates that, effective November 20, 2026, David Caplon has been appointed as the new CFO of Quantum Cyber N.V. Caplon, who previously served as the company's Controller, will now oversee the company's financial operations. The filing states, "In connection with Mr. Caragol’s resignation, the Board of Directors appointed David Caplon to serve as Chief Financial Officer of the Company." Additionally, Caplon will receive a base salary of $22,500 per month and is eligible for performance-based bonuses.
Impact
This leadership change may affect various stakeholders, including employees, investors, and partners within the pharmaceutical preparations industry. Caplon's experience in financial management and his previous role as Controller will likely influence the company's financial strategies moving forward. The continuity provided by Caragol's consulting agreement may also help mitigate any potential disruptions during this transition.
What's Next
The filing does not specify what happens next. However, Caplon's appointment may lead to further strategic initiatives and financial planning as the company continues to navigate the competitive landscape of the pharmaceutical industry.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





